Cancer pathways in malignant Research gliomas. App1010484 Scheme Priority-driven 2010 PdCCRS: Role of dietary Collaborative Cancer University of New compounds on PGC-1 alpha Cancer - 15/02/2011 36 Sydney NSW 2052 Australia South Wales methylation in colorectal Research cancer. App1010361 Scheme Priority-driven 2010 PdCCRS: Targeting drug Collaborative resistant genes in brain Cancer University of New Cancer cancer: delivery of siRNA to $49,500.00 15/02/2011 19 Sydney NSW 2052 Australia South Wales Research improve cancer therapy. Scheme App1003650 Priority-driven Autofluorescence imaging for Collaborative early detection and surgical Cancer University of Cancer margin delineation of oral $558,131.20 21/02/2011 44 St Lucia, QLD 4072 Australia Queensland Research cancers and pre-cancers. Scheme App1009996 Priority-driven Collaborative Cancer University of The role of CD123 in MDSA Cancer $316,276.40 24/02/2011 36 North Terrace, SA 5005 Australia Adelaide and AML. App1010336 Research Scheme 2010 PdCCRS: Whole Brain Priority-driven following local Collaborative Cancer University of treatment of intracranial Cancer $650,111.00 01/03/2011 60 Sydney, NSW 2006 Australia Sydney metastases of melanoma - a Research randomised phase III trial. Scheme App1009485 2010 PdCCRS: A randomised, placebo-controlled trial of Priority-driven concurrent cediranib Collaborative [AZD2171] with platinum - Cancer University of Cancer based chemotherapy & $270,597.80 01/03/2011 24 Sydney, NSW 2006 Australia Sydney Research maintenance cediranib in Scheme women with platinum sensitive relapsed ovarian cancer: ICON 6. App1006602 Priority-driven Collaborative 2010 PdCCRS: Tumour protein Cancer University of Cancer D52 over-expression and DNA $48,132.40 01/03/2011 12 Sydney, NSW 2006 Australia Sydney Research repair in cancer. App1007020 Scheme 2010 PdCCRS: START Phase III Priority-driven Study of Active Surveillance Collaborative Cancer University of Therapy Against Radical Cancer $329,320.20 01/03/2011 38 Sydney, NSW 2006 Australia Sydney Treatment in Patients Research Diagnosed with Favourable Scheme Risk Prostate Cancer.
Cancer Research Scheme pathways in malignant gliomas. App1010484 Cancer Australia Priority-driven Collaborative Cancer Research Scheme University of New South Wales 2010 PdCCRS: Role of dietary compounds on PGC-1 alpha methylation in colorectal cancer. App1010361 - 15/02/2011 36 Sydney NSW 2052 Cancer Australia Priority-driven Collaborative Cancer Research Scheme University of New South Wales 2010 PdCCRS: Targeting drug resistant genes in brain cancer: delivery of siRNA to improve cancer therapy. App1003650 $49,500.00 15/02/2011 19 Sydney NSW 2052 Cancer Australia Priority-driven Collaborative Cancer Research Scheme University of Queensland Autofluorescence imaging for early detection and surgical margin delineation of oral cancers and pre-cancers. App1009996 $558,131.20 21/02/2011 44 St Lucia, QLD 4072 Cancer Australia Priority-driven Collaborative Cancer Research Scheme University of Adelaide The role of CD123 in MDSA and AML. App1010336 $316,276.40 24/02/2011 36 North Terrace, SA 5005 Cancer Australia Priority-driven Collaborative Cancer Research Scheme University of Sydney 2010 PdCCRS: Whole Brain following local treatment of intracranial metastases of melanoma - a randomised phase III trial. App1009485 $650,111.00 01/03/2011 60 Sydney, NSW 2006 Cancer Australia Priority-driven Collaborative Cancer Research Scheme University of Sydney 2010 PdCCRS: A randomised, placebo-controlled trial of concurrent cediranib [AZD2171] with platinum - based chemotherapy & maintenance cediranib in women with platinum sensitive relapsed ovarian cancer: ICON 6. App1006602 $270,597.80 01/03/2011 24 Sydney, NSW 2006 Cancer Australia Priority-driven Collaborative Cancer Research Scheme University of Sydney 2010 PdCCRS: Tumour protein D52 over-expression and DNA repair in cancer. App1007020 $48,132.40 01/03/2011 12 Sydney, NSW 2006 Cancer Australia Priority-driven Collaborative Cancer Research Scheme University of Sydney 2010 PdCCRS: START Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favourable Risk Prostate Cancer. $329,320.20 01/03/2011 38 Sydney, NSW 2006
grants_reporting_20170703.docx